Literature DB >> 17385090

Cognitive impairment in adult myotonic dystrophies: a longitudinal study.

V Sansone1, S Gandossini, M Cotelli, M Calabria, O Zanetti, G Meola.   

Abstract

The clinical relevance and extent of cognitive impairment in adult myotonic dystrophy type 1 (DM1) and 2 (DM2) is still unclear. The aim of this study was to determine whether previously reported cognitive abnormalities progress over time and if this occurs in DM2 as it does in DM1. Fifty-six patients with DM1 and 29 patients with DM2 were subjected to muscle strength assessment, and to a complete battery of neuropsychological tests. Repeated assessment was performed in 20 DM1 and 13 DM2 over time (DM1 mean follow-up: 7.3+/-2.7 years; DM2 mean follow- up: 9.5+/-2.4 years). Muscle strength and test scores for frontal lobe functions worsened significantly over time (p<0.01), in both DM1 and DM2. DM2 is a progressive muscle disorder, although less severe than DM1. In both DM1 and DM2 frontal cognitive impairment (attentional) worsens over time but does not extend to additional areas of cognition.

Entities:  

Mesh:

Year:  2007        PMID: 17385090     DOI: 10.1007/s10072-007-0742-z

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  24 in total

1.  Myotonic dystrophies as a brain disorder.

Authors:  Giovanni Meola
Journal:  Neurol Sci       Date:  2010-10-06       Impact factor: 3.307

2.  Diagnostic odyssey of patients with myotonic dystrophy.

Authors:  James E Hilbert; Tetsuo Ashizawa; John W Day; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  J Neurol       Date:  2013-06-27       Impact factor: 4.849

3.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

4.  Frontostriatal dysexecutive syndrome: a core cognitive feature of myotonic dystrophy type 2.

Authors:  Stojan Peric; Gorana Mandic-Stojmenovic; Elka Stefanova; Dusanka Savic-Pavicevic; Jovan Pesovic; Vera Ilic; Valerija Dobricic; Ivana Basta; Dragana Lavrnic; Vidosava Rakocevic-Stojanovic
Journal:  J Neurol       Date:  2014-10-28       Impact factor: 4.849

5.  Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2.

Authors:  Stojan Peric; Vidosava Rakocevic Stojanovic; Gorana Mandic Stojmenovic; Vera Ilic; Masa Kovacevic; Aleksandra Parojcic; Jovan Pesovic; Milija Mijajlovic; Dusanka Savic-Pavicevic; Giovanni Meola
Journal:  Neurol Sci       Date:  2016-11-28       Impact factor: 3.307

6.  Longitudinal study in patients with myotonic dystrophy type 1: correlation of brain MRI abnormalities with cognitive performances.

Authors:  T Cabada; J Díaz; M Iridoy; P López; I Jericó; P Lecumberri; B Remirez; R Seijas; M Gomez
Journal:  Neuroradiology       Date:  2020-11-25       Impact factor: 2.804

7.  A 9-year follow-up study of quantitative muscle strength changes in myotonic dystrophy type 1.

Authors:  Cynthia Gagnon; Émilie Petitclerc; Marie Kierkegaard; Jean Mathieu; Élise Duchesne; Luc J Hébert
Journal:  J Neurol       Date:  2018-05-21       Impact factor: 4.849

8.  Retrospective study on PET-SPECT imaging in a large cohort of myotonic dystrophy type 1 patients.

Authors:  Vincenzo Romeo; E Pegoraro; F Squarzanti; G Sorarù; C Ferrati; M Ermani; P Zucchetta; F Chierichetti; C Angelini
Journal:  Neurol Sci       Date:  2010-09-15       Impact factor: 3.307

Review 9.  Myotonic Dystrophy Type 1 Management and Therapeutics.

Authors:  Cheryl A Smith; Laurie Gutmann
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

10.  Grey and white matter loss along cerebral midline structures in myotonic dystrophy type 2.

Authors:  Martina Minnerop; Eileen Luders; Karsten Specht; Jürgen Ruhlmann; Christiane Schneider-Gold; Rolf Schröder; Paul M Thompson; Arthur W Toga; Thomas Klockgether; Cornelia Kornblum
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.